❌

Reading view

Watch: EU health chief has ‘ashes’ thrown over him in protest at pesticide rules

BRUSSELS — Activists from a cancer survivor group threw what appeared to be ashes over the EU’s health chief in protest at Europe’s new rules relaxing pesticide use.

Commissioner for Health Olivér Várhelyi was about to deliver a speech at a cancer summit on the EU’s work to curb the disease when two protesters got on stage and threw a grey, dusty substance on him.  

“I am a cancer patient; I’m protesting against omnibus law,” said one of the activists from French group Cancer Colère. “These are the ashes of the people you will kill with the pesticides,” said another.  One of the protestors was Fleur Breteau, a French writer and activist. The other could not be identified.

The Commission presented the omnibus as a way to clear the backlog of pesticides waiting for approval, to make life easier for farmers. But it is strongly opposed by many civil society groups.

More than 2,000 scientists have signed a letter calling for the proposal to be put on hold until an independent impact assessment is carried out. Consumer group Foodwatch took the issue to the European Ombudsman, accusing the Commission of maladministration, and NGOs have organized multiple protests.

More than 300 NGOs — including environmental organizations, beekeepers’ associations and pesticide victims’ groups, plus doctors and scientists — from 25 European countries will gather outside the European Parliament in Strasbourg at 2 p.m. on Nov. 24 to express discontent with the omnibus.

Video taken at The Hotel in Brussels on Nov. 19, 2026. | Emma Pirnay/POLITICO

Várhelyi brushed off the dust, visibly displeased, and continued with his speech as planned.  

“What sort of people are you?” he remarked. “As I was saying, good morning, I’m a bit surprised that in the name of victims of cancer, they dare to splash the ashes of those who have died.”  

“This is beyond anything we could have imagined. We are sorry,” Elisabetta Zanon, head of the European Cancer Organisation, told the audience.  

  •  

Europe’s moment to lead: Backing research in a global race

Europe’s population is aging, with an increased burden of chronic diseases: more than half of adults in the European Union are now overweight and one in six is obese.1 In parallel, we are exposed to new threats from biosecurity, the malicious use of artificial intelligence, climate-related health threats and drug-resistant superbugs.

We are not passive bystanders. European teachers, biologists, nurses and manufacturers have all played a role in developing innovations that protect our populations and help them thrive. Now is not the time to step back. We believe health research and innovation are economic drivers of Europe’s future, not discretionary costs. Backing research in health as a pillar of our future in a global race is the right choice. It enables Europe to lead and support sustainable growth, as a pillar of the new architecture of global health.

We believe health research and innovation are economic drivers of Europe’s future, not discretionary costs.

The evidence is all around us. A vaccine developed against tuberculosis has been a frontline bladder cancer treatment for over 40 years,2 technology first developed for a malaria vaccine now helps protect millions against shingles,3 and mRNA research, developed over decades, enabled Europe’s fastest-ever vaccine response to Covid-19.4 Scientific progress rarely remains confined to the place or problem where it begins.

Public budgets are under pressure, but these achievements show what investment in global health research can deliver. Pressure can be a catalyst, focusing minds, sharpening priorities and turning constraints into innovative breakthroughs. Too often, the debate is framed in terms of what Europe gives. Too rarely is it framed in terms of what Europe and its people receive in return. With commitment, we can find pragmatic ways to maximize our investments as a union.

Building on its strengths in life sciences, Europe can advance its health sovereignty and seize the emerging opportunities in scientific discovery, next-generation vaccines and biomanufacturing. Basic and applied research become new technologies, intellectual property, skilled jobs and revenues that protect European health, growth and wealth. Together, these returns are Europe’s Health Dividend.

Europe’s health, security and prosperity depend on its ability to contribute to, and benefit from, global networks of research and innovation. Retreating from global research would not reduce vulnerability; it would increase it. Investing and engaging beyond our borders is a strategic imperative for Europe.

Retreating from global research would not reduce vulnerability; it would increase it. Investing and engaging beyond our borders is a strategic imperative for Europe.

At a time when public investment must deliver its value, we can find ways to maximize the impact of European money by working and funding a shared agenda together, not as disjointed nations. Health research remains one of the clearest examples of an investment that strengthens Europe’s future while delivering benefits today.

Back Europe’s Health Dividend. Sign the declaration.

SIGNATORIES

Europe’s Health Dividend is funded by the Gates Foundation and Coefficient Giving.


References

  1. Eurostat. Over half of adults in the EU are overweight. 4 September 2026. https://ec.europa.eu/eurostat/web/products-eurostat-news/w/ddn-20260904-1
  2. Kluemper A, Morris K, Mellon MJ. From plague to the promise: The journey of Bacille Calmette–Guérin. Bladder. 2024;11(4):e21200022. https://doi.org/10.14440/bladder.2024.0035
  3. Impact Global Health. From malaria research to protecting aging populations: AS01 Adjuvant in Shingrix. https://www.impactglobalhealth.org/insights/report-library/shingrix-vaccine
  4. European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. 21 December 2020. https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu

Disclaimer

POLITICAL ADVERTISEMENT

  • The sponsor is Europe’s Health Dividend.
  • The advertisement is linked to investment in global health research and development and its contribution to Europe’s health, security, resilience and economic competitiveness.

More information here.

  •  

How Health Systems Can Spot Risk Before a Crisis

Cancer claims 10 million lives each year, the global shortage of health workers runs into the millions, and in some parts of the world, a single mosquito bite can be fatal.

These challenges may seem very different. Yet they share a common element in how many health systems operate: risk is often recognised only after it has become illness, outbreak or crisis. By then, a disease may have advanced, transmission of disease may be under way, or an already stretched workforce may be managing consequences that earlier action could have reduced.

The opportunity is to move that point of intervention earlier. This is what anticipatory health means in practice: using signals that already exist, at the bedside, in communities, and in routine health data, to help people and health systems act sooner. It is not prediction for its own sake. The value lies in connecting early and everyday signals to a timely, practical response.

Finding practical routes to earlier action

That principle sits at the heart of the Future Health Impact Challenge: Building Anticipatory Health Systems through Population Sensing, launched by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. The Challenge received 393 submissions from 68 countries. ThinkMD, VectorCam and Huna emerged as its three award-winning solutions: ThinkMD received the grand prize, with VectorCam and Huna recognised as distinguished finalists.

Future Health Impact Challenge: Trailer

The Challenge was designed to identify practical solutions with evidence of impact and potential to scale. Each of the three selected teams demonstrated their approach to using technology to turn an early signal into decisions that support anticipatory actions a health system can take.

Frontline care as a population signal

ThinkMD starts with the interaction between a frontline health worker and a patient. Its offline mobile platform guides structured assessments aligned with clinical protocols, supporting providers where doctors, connectivity, and diagnostic tools may be scarce. Almost 10,000 frontline health workers across 885 facilities are now using it.

Each consultation also creates structured data. Across facilities, that information can reveal changes in symptoms and service demand. In Zambia, analysis of around one million encounters identified symptom patterns several months before a confirmed cholera outbreak. In Kenya, deployment data showed improvements in identifying danger signs in infants and prescribing antibiotics correctly for childhood pneumonia.

It is not prediction for its own sake.

“The utilisation of AI in healthcare is an absolute game changer. Not only can we increase access for patients, but we can also increase access to information to make correct and appropriate diagnoses and give the right treatment to the right patient at the right time. Future Health has been a really critical platform to be able to accelerate our mission of moving from reactionary to anticipatory care,” said Dr Jackie Rabec of ThinkMD.

The award has given ThinkMD support and visibility as it works to expand into new health systems and strengthen how frontline data becomes timely intelligence for decision-makers. That is one measure of the Challenge’s impact: helping proven solutions move towards sustained, wider adoption.

Earlier signals from the environment and routine data

VectorCam begins with the environment around a community. Using a low-cost smartphone imaging device and offline AI, community health workers can photograph and identify mosquitoes in the field. Each observation generates time- and location-based data that can help authorities see changing vector risk as the first signal of disease patterns, before a spread in local communities and populations.

The value lies in connecting early and everyday signals to a timely, practical response.

Field evaluations show data completeness rising from approximately 60% to more than 90%. With support from the Future Health Impact Challenge, VectorCam aims to strengthen its early-warning capability, integrate additional data sources and expand into national surveillance programmes.

Huna looks for earlier cancer-risk signals in information that health systems already generate. Its platform analyses routine complete blood count data to identify people with an elevated risk and prioritises them for screening. It does not diagnose cancer from a blood test; it helps direct limited screening capacity, and supports patients and healthcare professionals through the next steps.

In Brazil, Huna’s deployments have screened more than 500,000 people and detected hundreds of cancer cases. Its experience also highlights a critical ‘last mile’: identifying risk is not enough if a person does not complete the diagnostic pathway. Recognition and funding from the Challenge could help support further validation across new populations and facilitate new international partnerships.

Innovation is only the starting point

Together, these solutions show that useful signals can come from a variety of sources – including clinical encounters, environmental surveillance, and routine diagnostics. They also show that anticipatory approaches can be built where connectivity, specialist capacity, or access to screening is limited, and that innovation developed in those settings can share insights that can be localised and adopted globally.

But a successful technology or pilot is not the same as system-wide impact. Scaling requires local validation, integrated into existing workflows, responsible data governance, sustainable financing, workforce training, and evidence that earlier insight changes decisions and outcomes.

A successful technology or pilot is not the same as system-wide impact.

“The solutions emerging from this Challenge reflect both the urgency and the opportunity facing health systems globally. By bringing innovators together with policymakers, funders and implementers through platforms such as Future Health, we can help accelerate solutions that are locally grounded and capable of delivering impact at scale,” said Hala Hanna, Executive Director of MIT Solve.

From recognition to system-level impact

The Future Health Impact Challenge is part of Future Health’s wider role as a year-round platform for action. Together with our partners and colleagues across diverse sectors and geographies, Future Health identifies promising solutions, supports their development, builds international connections and brings together the policy, clinical, research and investment expertise needed to move from proof to concept to measurable impact.

The Future Health impact documentary film is now available to watch, and shares personal commentary from the founders of the three companies, local stories of the solutions in action, and commentary from the Challenge owners and collaborator.

Watch the full Future Health Impact Challenge Film here.

  •  
❌